Abstract：
Chronic prurigo (CPG) is a neuroinflammatory dermatosis characterized by prolonged pruritus lasting more than 6 weeks, pruriginous skin lesions, and repeated scratching. Patients with CPG suffer significantly from psychological distress and a marked impairment in their quality of life. The most common subtype of CPG is chronic nodular prurigo (CNPG, also called prurigo nodularis). In addition to the clinical features of CPG and the burden of disease, this CME article provides an overview of the significant advances in understanding the pathophysiology, including the associated therapeutic options for CPG. Dupilumab is the first approved therapy for moderate and severe CNPG to date from the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo-controlled trials. These include biologics such as nemolizumab (anti-IL-31-RA-mAb), vixarelimab/KPL-716 (anti-Oncostatin-M receptor β-mAb), and barzolvolimab/CDX-0159 (anti-KIT-mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine.
摘要：
慢性痒疹（CPG）是一种神经炎性皮肤病，其特征是持续超过6周的长期瘙痒，瘙痒性皮肤损伤，反复抓挠。CPG患者明显遭受心理困扰，生活质量明显受损。最常见的CPG亚型是慢性结节性痒疹（CNPG，也称为结节性痒疹）。除了CPG的临床特点和疾病负担外，这篇CME文章概述了在理解病理生理学方面的重大进展，包括CPG的相关治疗选择。Dupilumab是迄今为止欧洲药品管理局（EMA）和美国食品和药物管理局（FDA）批准的用于中度和重度CNPG的第一个治疗方法。它还强调了目前正在II期和III期临床研究的其他药物，随机化，安慰剂对照试验。这些包括生物制剂，如奈莫珠单抗（抗IL-31-RA-mAb），vixarelimab/KPL-716（抗瘤素M受体β-mAb），和barzolvolimab/CDX-0159（抗KIT-mAb），以及Janus激酶抑制剂，如波沃西替尼/INCB054707和abrocitinib，和阿片样物质调节剂如纳布啡。
